ubamatamab

Ubamatamab is a human IgG4-based bispecific monoclonal antibody that targets both Mucin 16 (MUC16), a cell surface glycoprotein overexpressed in several epithelial cancers, and cluster of differentiation 3 (CD3) on T cells. By bridging MUC16 on tumor cells and CD3 on T cells, ubamatamab promotes T cell–mediated cytotoxicity against cancer cells. It is designed to elicit polyclonal T-cell-mediated killing of MUC16-expressing tumor cells, even in the presence of high concentrations of CA‑125. Ubamatamab has demonstrated dose-dependent antitumor activity in preclinical models and is being evaluated for recurrent ovarian cancer, endometrial cancer, SMARCB1-deficient malignancies such as renal medullary carcinoma and epithelioid sarcoma, fallopian tube cancer, and peritoneal cancer. The drug is administered intravenously and developed by Regeneron Pharmaceuticals[1][2][4][5][6][7].

Other names

anti-muc16/cd3 bite antibody regn4018bispecific t-cell engager antibody regn4018muc16xcd3 bispecific t-cell engager regn4018muc-16xcd3 bispecific t-cell engager regn4018muc 16xcd3 bispecific t-cell engager regn4018anti MUC16-CD3 antibodyAnti-MUC16/CD3-BiTE-antibody-REGN4018antiMUC16-antiCD3-monoclonal-antibodiesantiMUC-16-antiCD3-monoclonal-antibodiesantiMUC 16-antiCD3-monoclonal-antibodiesBispecific-T-cell-engager-antibody-REGN-4018Bispecific-T-cell-engager-antibody-REGN4018Bispecific-T-cell-engager-antibody-REGN 4018BiTE-antibody-REGN-4018BiTE-antibody-REGN4018BiTE-antibody-REGN 4018MUC16xCD3-bispecific-monoclonal-antibodiesMUC-16xCD3-bispecific-monoclonal-antibodiesMUC 16xCD3-bispecific-monoclonal-antibodies